Skip Nav Destination
Issues
1 March 2012
-
Cover Image
Cover Image
Following treatment with a G-quadruplex ligand, telomestatin, glioma stem cells rapidly developed punctate nuclear 53BP1 foci. Of note, some of these foci colocalized with nontelomeric DNA, thereby representing both telomeric and nontelomeric dysfunction-induced foci, a hallmark of deprotected DNA damage. The loss of tumor stemness is likely associated with a failure in the DNA damage response elicited by telomestatin in glioma stem cells. For details, see the article by Miyazaki and colleagues on page 1268 of this issue.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR New Strategies
Molecular Pathways
Review
Human Cancer Biology
Activation of PI3K Signaling in Merkel Cell Carcinoma
Valentina Nardi; Youngchul Song; Juan A. Santamaria-Barria; Arjola K. Cosper; Quynh Lam; Anthony C. Faber; Genevieve M. Boland; Beow Y. Yeap; Kristin Bergethon; Vanessa L. Scialabba; Hensin Tsao; Jeffrey Settleman; David P. Ryan; Darrell R. Borger; Atul K. Bhan; Mai P. Hoang; Anthony J. Iafrate; James C. Cusack; Jeffrey A. Engelman; Dora Dias-Santagata
Cancer Therapy: Preclinical
Telomestatin Impairs Glioma Stem Cell Survival and Growth through the Disruption of Telomeric G-Quadruplex and Inhibition of the Proto-oncogene, c-Myb
Takeshi Miyazaki; Yang Pan; Kaushal Joshi; Deepti Purohit; Bin Hu; Habibe Demir; Sarmistha Mazumder; Sachiko Okabe; Takao Yamori; Mariano Viapiano; Kazuo Shin-ya; Hiroyuki Seimiya; Ichiro Nakano
Polymeric Nanoparticle-Encapsulated Hedgehog Pathway Inhibitor HPI-1 (NanoHHI) Inhibits Systemic Metastases in an Orthotopic Model of Human Hepatocellular Carcinoma
Yang Xu; Venugopal Chenna; Chaoxin Hu; Hai-Xiang Sun; Mehtab Khan; Haibo Bai; Xin-Rong Yang; Qing-Feng Zhu; Yun-Fan Sun; Anirban Maitra; Jia Fan; Robert A. Anders
Imaging, Diagnosis, Prognosis
[18F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells
Cathy C. Zhang; Zhengming Yan; Wenlin Li; Kyle Kuszpit; Cory L. Painter; Qin Zhang; Patrick B. Lappin; Tim Nichols; Maruja E. Lira; Timothy Affolter; Neeta R. Fahey; Carleen Cullinane; Mary Spilker; Kenneth Zasadny; Peter O'Brien; Dana Buckman; Anthony Wong; James G. Christensen
Epidermal Growth Factor Receptor Protein Detection in Head and Neck Cancer Patients: A Many-Faceted Picture
Juliette Thariat; Marie-Christine Etienne-Grimaldi; Dominique Grall; René-Jean Bensadoun; Anne Cayre; Frédérique Penault-Llorca; Laurence Veracini; Mireille Francoual; Jean-Louis Formento; Olivier Dassonville; Dominique De Raucourt; Lionel Geoffrois; Philippe Giraud; Séverine Racadot; Sylvain Morinière; Gérard Milano; Ellen Van Obberghen-Schilling
Human Prostate Cancer in a Clinically Relevant Xenograft Mouse Model: Identification of β(1,6)-Branched Oligosaccharides as a Marker of Tumor Progression
Tobias Lange; Sebastian Ullrich; Imke Müller; Michael F. Nentwich; Katrin Stübke; Susanne Feldhaus; Christine Knies; Olaf J.C. Hellwinkel; Robert L. Vessella; Claudia Abramjuk; Mario Anders; Jennifer Schröder-Schwarz; Thorsten Schlomm; Hartwig Huland; Guido Sauter; Udo Schumacher
High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
Kosuke Yoshihara; Tatsuhiko Tsunoda; Daichi Shigemizu; Hiroyuki Fujiwara; Masayuki Hatae; Hisaya Fujiwara; Hideaki Masuzaki; Hidetaka Katabuchi; Yosuke Kawakami; Aikou Okamoto; Takayoshi Nogawa; Noriomi Matsumura; Yasuhiro Udagawa; Tsuyoshi Saito; Hiroaki Itamochi; Masashi Takano; Etsuko Miyagi; Tamotsu Sudo; Kimio Ushijima; Haruko Iwase; Hiroyuki Seki; Yasuhisa Terao; Takayuki Enomoto; Mikio Mikami; Kohei Akazawa; Hitoshi Tsuda; Takuya Moriya; Atsushi Tajima; Ituro Inoue; Kenichi Tanaka; for The Japanese Serous Ovarian Cancer Study Group
Cancer Therapy: Clinical
Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
Andres Forero-Torres; Sven de Vos; Brad L. Pohlman; Maksim Pashkevich; Damien M. Cronier; Nam H. Dang; Susan P. Carpenter; Barrett W. Allan; James G. Nelson; Christopher A. Slapak; Mitchell R. Smith; Brian K. Link; James E. Wooldridge; Kristen N. Ganjoo
Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer
David S. Yoo; John P. Kirkpatrick; Oana Craciunescu; Gloria Broadwater; Bercedis L. Peterson; Madeline D. Carroll; Robert Clough; James R. MacFall; Jenny Hoang; Richard L. Scher; Ramon M. Esclamado; Frank R. Dunphy; Neal E. Ready; David M. Brizel
Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors
Dan M. Patterson; Martin Zweifel; Mark R. Middleton; Patricia M. Price; Lisa K. Folkes; Michael R.L. Stratford; Phil Ross; Sarah Halford; Jane Peters; Jai Balkissoon; Dai J. Chaplin; Anwar R. Padhani; Gordon J.S. Rustin
Predictive Biomarkers and Personalized Medicine
CD26 Overexpression Is Associated with Prolonged Survival and Enhanced Chemosensitivity in Malignant Pleural Mesothelioma
Keisuke Aoe; Vishwa Jeet Amatya; Nobukazu Fujimoto; Kei Ohnuma; Osamu Hosono; Akio Hiraki; Masanori Fujii; Taketo Yamada; Nam H. Dang; Yukio Takeshima; Kouki Inai; Takumi Kishimoto; Chikao Morimoto
Pathway-Specific Analysis of Gene Expression Data Identifies the PI3K/Akt Pathway as a Novel Therapeutic Target in Cervical Cancer
Julie K. Schwarz; Jacqueline E. Payton; Ramachandran Rashmi; Tao Xiang; Yunhe Jia; Phyllis Huettner; Buck E. Rogers; Qin Yang; Mark Watson; Janet S. Rader; Perry W. Grigsby
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
Robert C. Doebele; Amanda B. Pilling; Dara L. Aisner; Tatiana G. Kutateladze; Anh T. Le; Andrew J. Weickhardt; Kimi L. Kondo; Derek J. Linderman; Lynn E. Heasley; Wilbur A. Franklin; Marileila Varella-Garcia; D. Ross Camidge
Corrections
Advertisement